Related Experiment Videos
Nitric oxide in chronic renal failure.
Jens Passauer1, Frank Pistrosch, Eckhart Büssemaker
1Division of Nephrology, Department of Medicine, University Hospital Carl Gustav Carus, Dresden, Germany. passauer@rcs.urz.tu-dresden.de
Kidney International
|April 21, 2005
Summary
Patients with chronic renal failure exhibit reduced nitric oxide (NO) availability, impairing vascular function and potentially contributing to cardiovascular disease. This NO deficiency is linked to agonist-stimulated vasodilation, not baseline levels.
Area of Science:
- Cardiovascular Physiology
- Nephrology
- Vascular Biology
Background:
- Endothelium-derived nitric oxide (NO) is crucial for vascular homeostasis.
- Accelerated atherosclerosis and cardiovascular mortality in chronic renal failure (CRF) suggest a role for vascular dysfunction.
- A deficiency in vascular NO is hypothesized to contribute to these complications in uremic patients.
Purpose of the Study:
- To investigate the role of nitric oxide (NO) in vascular dysfunction in patients with chronic renal failure (CRF).
- To assess endothelium-dependent vasodilation and NO availability in uremic individuals.
Main Methods:
- Utilized the forearm blood flow technique to assess vascular tone and NO-mediated vasodilation.
- Evaluated agonist-induced endothelium-dependent vasodilation in uremic patients compared to controls.
Main Results:
- Baseline NO availability was found to be unimpaired in uremic patients.
- A significant reduction in agonist-induced endothelium-dependent vasodilation was observed in uremic patients.
- This impairment was primarily attributed to reduced vascular NO availability upon stimulation, with NO-independent pathways remaining intact.
Conclusions:
- Chronic renal failure is associated with impaired agonist-induced nitric oxide (NO) availability, contributing to endothelial dysfunction.
- Potential mechanisms include NO synthase uncoupling due to cofactor deficiency or increased oxidative stress.
- Further research is needed to elucidate specific mechanisms and therapeutic targets for NO deficiency in uremia.